Proton pump (H+/K+-ATPase) expression in human laryngeal seromucinous glands
Proton pump (H+/K+-ATPase) expression in human laryngeal seromucinous glands
复制标题
DOI：
10.1016/j.otohns.2005.07.036
复制
发表时间：
2005-11-01
影响因子：
3.4
通讯作者：
Haines, GK
中科院分区：
文献类型：
--
作者：
Altman, KW;Waltonen, JD;Haines, GK
目的：最近的初步研究表明，H+/K(+)ATPase(质子泵)是喉咽反流病(LPRD)药物治疗的靶点，与人类喉粘膜下腺有关。本研究的假设是质子泵在人的喉部表达，而不是仅与胃的壁细胞有关。方法：15例(27例病理标本)的喉部手术标本经人类受试者委员会批准后，从喉部组织中获得含浆液腺的标本。储存的人胃组织也作为阳性对照和阴性对照。用两种与H+/K(+)ATPase(质子)泵的α或β亚基选择性反应的单抗进行免疫组织化学染色。结果：在15例受试者中，14例喉部呈阳性。26个标本在浆液细胞和导管中显示出一致的α亚基染色，23个标本显示β亚单位染色一致。胃壁细胞对质子泵的α和β亚基均呈强阳性染色。结论：H+/K+-ATPase(质子)泵存在于人喉的浆液细胞和喉管中，并有一定的表达差异。人类喉浆液粘液腺的质子泵参与可能解释了那些被认为患有LPRD的慢性喉炎患者喉部敏感性升高的原因。此外，质子泵抑制剂药物疗法可能在人类喉部有作用部位，这解释了可归因于LPRD的一些争议。EBM评级：B-3。(C)2005年美国耳鼻喉科学会-头颈外科基金会，Inc.保留所有权利。
OBJECTIVE: Recent pilot research suggested that the H+/K(+)ATPase (proton pump), which is the target of pharmacotherapy for laryngopharyngeal reflux disease (LPRD), is associated with human laryngeal submucosal glands. The hypothesis of this study is that proton pump is expressed in the human larynx, and is not solely associated with the parietal cells of the stomach.METHODS: Fifteen surgical larynx subjects (27 pathologic specimens) containing seromucinous glands from banked tissue were retrospectively obtained after approval from Human Subjects Committee. Banked human stomach tissue was also obtained for comparative positive and negative controls. Sections were immunostained with two monoclonal antibodies selectively reactive with alpha or beta subunits of the H+/K(+)ATPase (proton) pump.RESULTS: In the human larynx, positive staining was seen in 14 of 15 subjects. Twenty-six specimens showed consistent staining in the seromucinous cells and ducts for the alpha subunit, and 23 specimens for the beta subunit. Stomach parietal cells exhibited strongly positive staining for both the alpha and beta subunits of the proton pump. There was no staining In stomach cells that were not morphologically consistent with the parietal cell.CONCLUSION: The H+/K+-ATPase (proton) pump is present in seromucinous cells and ducts in the human larynx, with some variable expression noted. Proton pump involvement in human laryngeal seromucinous glands may explain heightened laryngeal sensitivity in those patients with chronic laryngitis believed to have LPRD. Also, proton pump inhibitor pharmacotherapy may have a site of action in the human larynx, explaining some of the controversies attributable to LPRD.EBM RATING: B-3.(C) 2005 American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. All rights reserved.